Kit Hunter Gordon
Directeur Général chez The Summit Group Ltd.
Profil
Mr. Kit H.
Gordon is Chairman & Managing Partner at Seraphim Capital (General Partner) LLP.
Mr. Gordon also served on the board at Sirigen Group Ltd.
Postes actifs de Kit Hunter Gordon
| Sociétés | Poste | Début |
|---|---|---|
Seraphim Capital (General Partner) LLP
 Seraphim Capital (General Partner) LLP Investment ManagersFinance Seraphim Capital (General Partner) LLP, a subsidiary of YFM Equity Partners LLP, is a venture capital firm founded in 2006. The firm is headquartered in London, the United Kingdom. | Private Equity Investor | 01/09/2006 |
The Summit Group Ltd.
 The Summit Group Ltd. Financial ConglomeratesFinance The Summit Group Ltd. provides investment services. The British company was founded in 1985 by Kit Hunter Gordon, who has been the CEO since then. | Directeur Général | 01/01/1985 |
Resources for Autism
 Resources for Autism Miscellaneous Commercial ServicesCommercial Services Resources for Autism provides social services. The non-profit company is based in London, UK. | Directeur/Membre du Conseil | - |
Anciens postes connus de Kit Hunter Gordon
| Sociétés | Poste | Fin |
|---|---|---|
Sirigen Group Ltd.
 Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Seraphim Capital (General Partner) LLP
Seraphim Capital (General Partner) LLP Investment ManagersFinance Seraphim Capital (General Partner) LLP, a subsidiary of YFM Equity Partners LLP, is a venture capital firm founded in 2006. The firm is headquartered in London, the United Kingdom. | Finance |
Sirigen Group Ltd.
Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality. | Process Industries |
Resources for Autism
Resources for Autism Miscellaneous Commercial ServicesCommercial Services Resources for Autism provides social services. The non-profit company is based in London, UK. | Commercial Services |
The Summit Group Ltd.
The Summit Group Ltd. Financial ConglomeratesFinance The Summit Group Ltd. provides investment services. The British company was founded in 1985 by Kit Hunter Gordon, who has been the CEO since then. | Finance |